TWi Biotechnology Inc. Announces Agreement with Castle Creek Pharmaceuticals, LLC

 

TAIPEI, Taiwan, Dec. 17, 2015TWi Pharmaceuticals, Inc. (4180.TT) today announced that its subsidiary, TWi Biotechnology, Inc. (TWiB), and Castle Creek Pharmaceuticals, LLC (CCP), a spin off entity from Marathon Pharmaceuticals, LLC, have entered into a development and commercialization agreement for its lead drug candidate AC-203, which is currently in development for the treatment of epidermolysis bullosa (EB). Under the terms of the agreement, TWiB grants to CCP an exclusive license of AC-203, covering a worldwide territory with the exception of Asia but including Australia and New Zealand, to develop, register and commercialize AC-203. TWiB is eligible to receive an upfront payment and milestone payments based on achievement of predefined clinical and regulatory events and will receive double-digit royalties after product launch. TWiB and CCP will collaborate globally for AC-203 product development in any other future indications.

Subscribe to get the latest news